A
Anat Mirelman
Researcher at Tel Aviv Sourasky Medical Center
Publications - 246
Citations - 12440
Anat Mirelman is an academic researcher from Tel Aviv Sourasky Medical Center. The author has contributed to research in topics: Medicine & Gait (human). The author has an hindex of 47, co-authored 208 publications receiving 9246 citations. Previous affiliations of Anat Mirelman include Harvard University & Ben-Gurion University of the Negev.
Papers
More filters
Journal ArticleDOI
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Ellen Sidransky,Mike A. Nalls,Jan O. Aasly,Judith Aharon-Peretz,Grazia Annesi,Egberto Reis Barbosa,Anat Bar-Shira,Daniela Berg,Jose Bras,Jose Bras,Alexis Brice,Alexis Brice,Chiung-Mei Chen,Lorraine N. Clark,Christel Condroyer,Elvira Valeria De Marco,Alexandra Durr,Alexandra Durr,Michael J. Eblan,Stanley Fahn,Matthew J. Farrer,Hon-Chung Fung,Ziv Gan-Or,Thomas Gasser,Ruth Gershoni-Baruch,Ruth Gershoni-Baruch,Nir Giladi,Nir Giladi,Alida Griffith,Tanya Gurevich,Tanya Gurevich,Cristina Januário,Peter Kropp,Anthony E. Lang,Guey Jen Lee-Chen,Suzanne Lesage,Karen Marder,Ignacio F. Mata,Anat Mirelman,Jun Mitsui,Ikuko Mizuta,Giuseppe Nicoletti,Giuseppe Nicoletti,Catarina R. Oliveira,Ruth Ottman,Avi Orr-Urtreger,Lygia da Veiga Pereira,Aldo Quattrone,Aldo Quattrone,Ekaterina Rogaeva,Arndt Rolfs,Hanna Rosenbaum,Roberto Rozenberg,Ali Samii,Ali Samii,Ali Samii,Ted Samaddar,Claudia Schulte,Manu Sharma,Manu Sharma,Andrew B. Singleton,Andrew B. Singleton,Mariana Spitz,Mariana Spitz,Eng-King Tan,Eng-King Tan,Nahid Tayebi,Tatsushi Toda,André R. Troiano,Shoji Tsuji,Matthias Wittstock,Tyra G. Wolfsberg,Yih-Ru Wu,Cyrus P. Zabetian,Yi Zhao,Shira G. Ziegler +75 more
TL;DR: Data collected demonstrate that there is a strong association between GBA mutations and Parkinson's disease, and those with a GBA mutation presented earlier with the disease, were more likely to have affected relatives, and were morelikely to have atypical clinical manifestations.
Journal ArticleDOI
Executive Control Deficits as a Prodrome to Falls in Healthy Older Adults: A Prospective Study Linking Thinking, Walking, and Falling
Talia Herman,Anat Mirelman,Anat Mirelman,Nir Giladi,Nir Giladi,Avraham Schweiger,Jeffrey M. Hausdorff,Jeffrey M. Hausdorff,Jeffrey M. Hausdorff +8 more
TL;DR: Among healthy older adults, individuals with poorer EF are more prone to falls, and optimal screening, early detection, and treatment of falls should, apparently, also target this cognitive domain.
Journal ArticleDOI
Executive Function and Falls in Older Adults: New Findings from a Five-Year Prospective Study Link Fall Risk to Cognition
Anat Mirelman,Anat Mirelman,Talia Herman,Marina Brozgol,Moran Dorfman,Elliot Sprecher,Avraham Schweiger,Nir Giladi,Nir Giladi,Jeffrey M. Hausdorff,Jeffrey M. Hausdorff,Jeffrey M. Hausdorff +11 more
TL;DR: Among community-living older adults, the risk of future falls was predicted by performance on EF and attention tests conducted 5 years earlier, indicating that screening EF will likely enhance fall risk assessment, and that treatment of EF may reduce fall risk.
Journal ArticleDOI
Virtual Reality for Gait Training: Can It Induce Motor Learning to Enhance Complex Walking and Reduce Fall Risk in Patients With Parkinson's Disease?
Anat Mirelman,Inbal Maidan,Talia Herman,Judith E. Deutsch,Nir Giladi,Jeffrey M. Hausdorff,Jeffrey M. Hausdorff,Jeffrey M. Hausdorff +7 more
TL;DR: The results indicate that TT + VR is viable in PD and may significantly improve physical performance, gait during complex challenging conditions, and even certain aspects of cognitive function.
Journal ArticleDOI
Gait impairments in Parkinson's disease.
Anat Mirelman,Anat Mirelman,Paolo Bonato,Richard Camicioli,Terry D. Ellis,Nir Giladi,Nir Giladi,Jamie L. Hamilton,Chris J. Hass,Jeffrey M. Hausdorff,Jeffrey M. Hausdorff,Jeffrey M. Hausdorff,Elisa Pelosin,Quincy J. Almeida +13 more
TL;DR: It is important to establish clear links between specific gait impairments, their underlying mechanisms, and disease progression to foster the acceptance and usability of quantitative gait measures as outcomes in future disease-modifying clinical trials.